Adherence to COPD free triple inhaled therapy in the real world: a primary care based study.
Alberto ZucchelliDavide L VetranoElisa BianchiniFrancesco Paolo LombardoAlessio PirainoMarco ZibelliniAlberto RicciAlessandra MarengoniFrancesco LapiClaudio CricelliPublished in: The clinical respiratory journal (2020)
The 85% of enrolled patients showed poor adherence to free triple inhaled therapy. Comorbidities, such as heart failure (OR 1.78, 95%CI 1.19-2.75), depression (OR 1.41, 95%CI 1.06-1.88) and peripheral vascular disease (OR 1.32, 95%CI 1.01-1.74) were associated with poor adherence. Former (OR 0.52, 95%CI 0.34-0.78) or current smokers (OR 0.61, 95%CI 0.41-0.93) and patients with more severe airways obstruction or history of severe exacerbations (OR 0.64, 95%CI 0.52-0.79) were less likely to exhibit poor adherence. Real-world adherence to triple inhaled therapy with different inhalers is generally low. Higher GOLD airways obstruction stage and current or former smoking status are associated with increased adherence to treatment. Reduced perceived benefit on symptoms control is probably linked to poorer adherence to free triple therapy.
Keyphrases
- cystic fibrosis
- heart failure
- primary care
- chronic obstructive pulmonary disease
- glycemic control
- depressive symptoms
- newly diagnosed
- stem cells
- ejection fraction
- type diabetes
- smoking cessation
- metabolic syndrome
- chronic kidney disease
- adipose tissue
- left ventricular
- mesenchymal stem cells
- bone marrow
- skeletal muscle
- social support
- sleep quality
- air pollution
- combination therapy
- weight loss
- replacement therapy